A retrospective study conducted in Japan showed that among 20,516 advanced NSCLC patients with EGFR-sensitive mutation, the total incidence rate of ILD or immune pneumonia was 4.8%; the incidence rates of pneumonia were 4.6% and 6.4% when treated with TKIs or nivolumab, respectively, and 25.7% in the combination therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.